article thumbnail

Pfizer buys immuno-inflammatory firm Arena Pharmaceuticals for $6.7b

Outsourcing Pharma

The pharmaceutical company currently has several promising treatments in development for gastroenterological, dermatological, and cardiological conditions.

article thumbnail

Shields Health Solutions’ New Collaboration to Boost Specialty Pharmacy Access in Chronic Care

XTalks

This collaboration aims to support patients with chronic and complex conditions, particularly in oncology, rheumatology and dermatology. million specialty care expansion in California, aimed at increasing access to cardiology, neurology and urology care, adding 44 physicians to meet rising patient needs.

Pharmacy 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Regulator and Funder? FDA’s Orphan Products Grants Program awards significant funding to help move promising treatments through clinical development

FDA Law Blog

These have included clinical trials for rare diseases across metabolic (n=5), oncology (n=5), cardiology (n=3), dermatology (n=3), pulmonary (n=3), hematology (n=2), hepatology (n=2), ocular (n=2), transplant (n=1), gastrointestinal (n=1), immunology (n=1), infectious (n=1), neurology (n=1), orthopedic (n=1), and toxicology (n=1) indications.

article thumbnail

Pfizer Completes Acquisition of Arena Pharmaceuticals

The Pharma Data

With a focus on immuno-inflammatory conditions in Rheumatology, Gastroenterology and Medical Dermatology, our current portfolio of approved medicines and investigational molecules spans multiple action and delivery mechanisms, from topicals to small molecules, biologics and biosimilars.

article thumbnail

Nine for 2021: The COVID-19 legacy

pharmaphorum

An IQVIA survey to Neurology, Cardiology, Rheumatology, Dermatology and Ophthalmologists in June 2020 across the lead five European countries showed an average of 30% of patients either “no shows” or still waiting for treatment that was delayed.

Sales 105
article thumbnail

Predicting heart disease from the skin

Scienmag

Jefferson researchers find that the genetic underpinnings of a skin disorder at birth indicate future heart problems PHILADELPHIA – Our skin tells us when we’ve spent too much time in the sun or when the dry air of winter has sucked away too much moisture. Now Jefferson researchers find that the skin can also foretell […].

article thumbnail

Novartis key growth drivers and launches continue momentum in Q1, maintaining confidence in growth. Group guidance for FY 2021 confirmed. | Novartis

The Pharma Data

COVID-19 negatively impacted demand, particularly: dermatology, ophthalmology, the breast cancer portfolio, Sandoz Retail and Anti-Infectives. Topline results will be presented at the American College of Cardiology 70th Annual Scientific Session. Adakveo sales reached USD 37 million. The safety profile of Entresto was confirmed.

Sales 40